Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma
This case suggests that residual IL-6 suppression from prior tocilizumab therapy may attenuate the severity of subsequent irAEs, permitting effective management without compromising anti-tumor efficacy. IL-6 modulation could be a promising strategy to improve the therapeutic index of dual checkpoint inhibition in MPM.
Authors
- Kentaro Noda (ORCID: https://orcid.org/0000-0001-8921-1944)
- Hiroshi Kojima
- Hidefumi Shimizu
- Asako Yanagisawa
- T. Fukaya
Institutions
- Japan Community Healthcare Organization (JP)
- Tokyo Yamate Medical Center (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-31
- DOI
- https://doi.org/10.3389/fonc.2025.1671503
- Citations
- 2
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.04